Cancel

Links to sites outside of sdachurchsierraleone.org are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


Continue

You are leaving Takeda.com

Takeda - Global

EPD-3055 OneTrust Cookie

EPD-3519 Schema Script

EPD-2855 GTM Script

EPD-4037 Matomo Tag Manager

EPD-4268 Cookie Script Hack

Access all Takeda investor-related information including financial reports, earnings, quarterly reports, and IR events. 

Investor Information  | Takeda Pharmaceuticals

Investor

# Investors



We bring our values to life through actions based on Patient-Trust-Reputation-Business, in that order. We believe that if we focus first on Patients, Trust and Reputation, we know we will build a sustainable and high performing Business. These unwavering values are embedded in our global business model to create long term-value for patients, shareholders and society.


Financial statements, per-share information and principal business indexes. 

Investor and shareholder events and related materials, notices of convocation, business reports, etc.

Sign up to receive our monthly newsletter, news release alerts and event information.

The values we believe in. The people who live them.

Answers to frequently asked questions from retail investors.

Find out how our financial, sustainability and other impacts are creating value in the short, medium and long term, and the focus areas we believe are most important for the stakeholders and communities we serve.


## Annual Integrated Report



Our world-class R\&D is focused on developing medicines and vaccines that will have a lasting impact on society and can make a critical difference to the lives of patients with limited or no options for treatment. Our R\&D pipeline is a clear demonstration of how we are working to deliver unique value to patients.


## Innovation



**Development pipeline by phase and therapeutic area**


**Expected timelines of key development programs**


We continue to actively enrich the pipeline through our in-house R&D capabilities, external partnerships and targeted business development that align with our core therapeutic areas.
Learn more about our R&D efforts [here](http://qz.sdachurchsierraleone.org/science/research-and-development/).


Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

## Sign up for our investors newsletter



View our policies and processes for how our company is managed

Download our Corporate Overview, media assets and more 

## Explore



## Disclaimer

This website contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on the judgments derived from the information available to the Company at the time of issuance of this site.

All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward-looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend," or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward-looking statements contained in this presentation. These risks and uncertainties include, but are not limited to,

1.  the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide;

2.  competitive pressures;

3.  applicable laws and regulations;

4.  the success or failure of product development programs;

5.  decisions of regulatory authorities and the timing thereof;

6.  changes in exchange rates;

7.  claims or concerns regarding the safety or efficacy of marketed products or product candidates;

8.  integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.

The information on this website is provided for informational purposes and should not be construed as a solicitation of an investment in our securities.

You should rely on your own independent examination of us before investing in any securities issued by our company.
